Marksans Pharma

Reasons for buying:

Buy PE was reasonable at 11.81 and below 10 years PE median of 18.12. The shares are worth keeping for the long term.

Earnings have increased 5 times since 2013 but lackluster and 10-Year average revenue growth is 16.18%.

Return on equity is excellent at 31.34% but the 5-year average is 22.57%.

The market cap of the company is ₹2,447.70cr.

The debt of the company is ₹18.74 cr with ₹212.29 cr in cash.

Buy date: 18-Aug-2021

Qty: 137 Buy Price: ₹72.65 Buy EPS: 6.15 Buy PE: 11.81

The price of the stock is down about -18.83% from my buy price.

The price has dropped 10% and has added 10k worth of shares. EPS is down -1.79% to 6.04.

Buy date: 25-Oct-2021

Qty: 153 Buy Price: ₹64.85 Buy EPS: 6.15 Buy PE: 10.54

The price has dropped another 10% and has added 10k worth of shares.

Buy date: 15-Nov-2021

Qty: 172 Buy Price: ₹58 Buy EPS: 6.04 Buy PE: 9.60

Marksans Pharma Ltd is a pharmaceutical company. It s engaged in the manufacturing and marketing of pharmaceutical formulations. It manufactures analgesics, expectorants, anti-diabetic, cardiovascular, central nervous system, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. The company also offers Contract Research and Manufacturing Services (CRAMS) to pharmaceutical companies. It has a global market presence with the majority of the revenue generated from North America, Europe, and the United Kingdom.